I’ve elected to start aggregating more content, beyond simply my posts, on Life Science Deal Flow. The starting place is interesting white papers I come across – note the new tab at the top of the LSDF site. If you have a paper you would like reviewed and shared with the LSDF community please be [...]

• 662http://clsdf.com/2009/12/white-papers-biomarkers-and-the-biology-of-web-2-0/White+Papers+%7C+Biomarkers+and+the+Biology+of+Web+2.02009-12-07+04%3A25%3A57admin

“You can accomplish anything in life, provided you do not mind who gets the credit.”
- Harry S. Truman
Apologies for the quiescent-state at LSDF this past week. While taking in some R&R in blissful Aspen, CO I found myself at one of my favorite bookstores, Explore Booksellers, on Main St. where an idea for a substantial [...]

• 612http://clsdf.com/2009/11/the-cell-cycle-entrepreneurial-leadership/The+Cell+Cycle+%26+Entrepreneurial+Leadership2009-11-16+18%3A29%3A56admin

The mere fact that Burrill & WR Hambrecht are touting their team-up to focus on bringing life science companies to the public markets is certainly big news. A savvy salt & pepper life science CEO (who orchestrated a >$1B M&A of his small cap clinical-stage entity) turned managing partner of a Sand Hill Rd. [...]

• 585http://clsdf.com/2009/11/2010-impending-bio-ipo-pandemonium-part-2/2010+%7C+Impending+Bio+IPO+Pandemonium%21+Part+%2322009-11-02+02%3A37%3A05admin

2009 unambiguously marked a thawing of the bio IPO market – who froze up at the tail end of 2007 – by featuring six offerings, and a seventh filed that may still travel along the neon lights of the midtown Manhattan Nasdaq ticker before we see Dick Clark and friends ring in 2010 from just [...]

• 566http://clsdf.com/2009/10/2010-impending-bio-ipo-pandemonium-part-1/2010+%7C+Impending+Bio+IPO+Pandemonium%21+%28Part+%231%292009-10-31+04%3A55%3A08admin

[Update #3] This is fast becoming perhaps my favorite post to update because it is the catalytic properties of the sometimes elusive to isolate GREEN enzyme that can enable so much good. That said, today’s new fund to report on, Mission Bay Capital (no website, yet…), though small in size, it is a seed fund [...]

• 556http://clsdf.com/2009/10/update-3-looking-for-some-more-of-this/UPDATE+%233+%7C+Looking+for+Some+%28MORE%29+of+This%3F2009-10-28+14%3A36%3A33admin

Thanks very much for your patience as we work diligently to re-launch the Life Science Deal Flow blog. We will be back on online Monday 19 October, not necessarily rested rather getting after it to bring you the latest on early-stage therapeutic, diagnostic and device companies – the news breaking, the funds raised, the investors [...]

• 457http://clsdf.com/2009/10/we%e2%80%99ll-be-right-back/We%E2%80%99ll+Be+Right+Back%212009-10-13+15%3A29%3A35admin

In recognition of October as Breast Cancer Awareness Month [C]LSDF is highlighting a few of the early-stage entities who are on the front-line in the battle against breast cancer that have been recently funded and are offering interesting scientific approaches in an effort to yield novel potential treatments, diagnostics and cures.
If you are interested in [...]

• 450http://clsdf.com/2009/10/october-breast-cancer-awareness-month/October+%7C+Breast+Cancer+Awareness+Month2009-10-04+18%3A10%3A00admin

The Rocky Mountain Life Science Investor Conference yielded a sense of sophistication and intensity catalyzed by the aggregation of high-quality presenting companies and top-tier venture and corporate investors. I was hardly surprised that then rumor, hearsay and innuendo combined to yield quite a bit of buzz throughout the oak paneled hallways of the Ritz Carlton [...]

• 448http://clsdf.com/2009/10/tape-delay-from-the-rmlsic-that%e2%80%99s-a-wrap/Tape-Delay+from+the+RMLSIC+%7C+That%E2%80%99s+a+Wrap%212009-10-01+13%3A55%3A00admin

[Update | Add Domain Associates, Domain Partners, VIII $500M to the early-stage drug and device sectors; bringing recently closed funds up to $1,925M]
Recently Boston, MA-based Excel Venture Management announced the close of the new $125M Excel Medical Fund. The portfolio is a planned balance across healthcare IT and services, diagnostics, and medical devices, plus life [...]

• 447http://clsdf.com/2009/09/looking-for-some-of-this/Looking+for+Some+of+This%3F2009-09-30+13%3A54%3A00admin

CLSDF continues to maintain keen watch on the thawing of the public equity markets, calibrated in a semi-quantitative approach via the life science IPO pricings. If all three of the current filings get out priced ‘as-is’ I would then call the score FINANCING EVENT 3 & LIQUIDITY OPPORTUNITY 2. A nice balance and it makes [...]

• 442http://clsdf.com/2009/09/anthera-working-to-thaw-the-markets/Anthera+%7C+Working+to+Thaw+the+Markets2009-09-23+05%3A48%3A00admin

Now this is interesting! The Food and Drug Administration’s Center for Drug Evaluation and Research, in collaboration with FDA’s Center for Biologics Evaluation and Research, Center for Veterinary Medicine, and Center for Devices and Radiological Health, has announced a public hearing (scheduled for 12 & 13 November in Washington DC) to discuss issues related to [...]

• 440http://clsdf.com/2009/09/fda-2-0%e2%80%a6really/FDA+2.0%E2%80%A6Really%3F2009-09-22+02%3A49%3A00admin

UPDATE (Breakfast) – Roy Davis, VP Corporate Development at Johnson & Johnson (NYSE: JNJ) and President JNJ Development Corporation opened the first full day of the RMLIC. He focused on “Creating New Business Opportunities at Johnson & Johnson” and stressed how a targeted focus on fostering innovation outside the entity (in addition to internal development) [...]

• 437http://clsdf.com/2009/09/live-blogging-from-the-rmlsic/Live+Blogging+from+the+RMLSIC2009-09-17+03%3A41%3A00admin

UPDATE: Lots can happen between an early morning blog post and the end of the business day. In this case Omeros has set its IPO terms; 6.82M common shares offered between $10 and $12 per share. So the company is hoping to raise between $68.2 and $81.8M. The planned ticker to trade under [...]

• 436http://clsdf.com/2009/09/1-ipo-2-ipo-3-ipo/1+IPO%21+2+IPO%3F%3F+3+IPO%3F%3F%3F2009-09-16+14%3A21%3A00admin